SCHEMBL21145532

SCHEMBL21145532

CC(C)(C)OC(=O)N1CCCCCCC(O)(O)CCCC1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.58
SMN1; SMN2 Q16637 2/20 0.50
USP2 O75604 1/20 0.50
EPHX1 P07099 1/20 0.48
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
ABL1 P00519 1/20 0.43
RIN1 Q13671 1/20 0.43
MAPT P10636 3/20 0.43
ALDH1A1 P00352 1/20 0.43
PREP P48147 2/20 0.42
EPHX2 P34913 1/20 0.42
RECQL P46063 1/20 0.41
NPC1 O15118 1/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21145819 1.00 HPGD (0.58) HPGDSMN1; SMN2USP2EPHX1MEN1
SCHEMBL21142647 0.88 HPGD (0.56) HPGDSMN1; SMN2USP2EPHX1MEN1
SCHEMBL21145918 0.88 HPGD (0.56) HPGDSMN1; SMN2USP2EPHX1MEN1
SCHEMBL18432213 0.87 HPGD (0.71) HPGDSMN1; SMN2USP2EPHX1MEN1
SCHEMBL18097955 0.87 HPGD (0.71) HPGDSMN1; SMN2USP2EPHX1MEN1
SCHEMBL19852529 0.87 HPGD (0.71) HPGDSMN1; SMN2USP2EPHX1MEN1
SCHEMBL19864899 0.87 HPGD (0.71) HPGDSMN1; SMN2USP2EPHX1MEN1
SCHEMBL21707988 0.87 HPGD (0.71) HPGDSMN1; SMN2USP2EPHX1MEN1
SCHEMBL60470 0.87 HPGD (0.71) HPGDSMN1; SMN2USP2EPHX1MEN1
SCHEMBL2077166 0.87 HPGD (0.71) HPGDSMN1; SMN2USP2EPHX1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11186564-B2 Dual NAV1.2/5HT2a inhibitors for treating CNS disorders SUNOVION PHARMACEUTICALS INC. (US) 2021-11-30 US disclosed
US-20190194163-A1 DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2019-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190194163-A1 DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS SCN2A, HTR2A, HTR2C HPGD 3689/4885SMN1; SMN2 341/4885USP2 3106/4885
US-11186564-B2 Dual NAV1.2/5HT2a inhibitors for treating CNS disorders SCN2A, HTR2A, HTR2C HPGD 3689/4885SMN1; SMN2 341/4885USP2 3106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.